{"id":"18f-dopa","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure"},{"rate":null,"effect":"Allergic reaction to tracer"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"18F-DOPA is a fluorine-18 labeled precursor of dopamine used as a PET tracer. It crosses the blood-brain barrier and is taken up by dopaminergic neurons via the large neutral amino acid transporter, where it is converted to 18F-dopamine. This allows imaging of dopamine synthesis capacity and neuronal integrity in conditions affecting the dopaminergic system.","oneSentence":"18F-DOPA is a positron emission tomography (PET) imaging agent that accumulates in dopamine-producing tissues, allowing visualization of dopaminergic function and neurological disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:56:25.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Imaging of dopaminergic function in Parkinson's disease and parkinsonian syndromes"},{"name":"Evaluation of pediatric movement disorders and neurological conditions affecting dopamine synthesis"}]},"trialDetails":[{"nctId":"NCT03648905","phase":"","title":"Clinical Laboratory Evaluation of Chronic Autonomic Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2018-09-06","conditions":"Parkinson's Disease, Multiple System Atrophy, Autonomic Failure","enrollment":89},{"nctId":"NCT02019706","phase":"PHASE2","title":"Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-02-12","conditions":"ACTH, Cushing's Syndrome","enrollment":80},{"nctId":"NCT00024622","phase":"","title":"PET Scanning in Parkinson s Disease","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2002-03-15","conditions":"Schizophrenia, Parkinson's Disease","enrollment":502},{"nctId":"NCT00004847","phase":"PHASE1","title":"Diagnosis of Pheochromocytoma","status":"RECRUITING","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2000-03-22","conditions":"Pheochromocytoma, Endocrine Disease, Endocrine Diseases","enrollment":3000},{"nctId":"NCT00646022","phase":"","title":"Natural History of Familial Carcinoid Tumor","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2008-08-25","conditions":"Carcinoid","enrollment":1600},{"nctId":"NCT04246437","phase":"PHASE1","title":"[18F]F-DOPA Imaging in Patients With Autonomic Failure","status":"RECRUITING","sponsor":"Daniel Claassen","startDate":"2020-02-04","conditions":"Autonomic Failure, Pure Autonomic Failure, Parkinson Disease","enrollment":40},{"nctId":"NCT06667726","phase":"PHASE2","title":"An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-10-01","conditions":"Malignant Brain Neoplasm","enrollment":47},{"nctId":"NCT06349213","phase":"","title":"Uncovering the Cognitive and Neural Mechanisms Underlying Cognitive Time","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2024-11-20","conditions":"Healthy Aging","enrollment":130},{"nctId":"NCT04706910","phase":"PHASE3","title":"18F-DOPA II - PET Imaging Optimization","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2021-01-20","conditions":"Congenital Hyperinsulinism, Neuroblastoma, Parkinson Disease","enrollment":800},{"nctId":"NCT05653622","phase":"PHASE2","title":"Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma","status":"RECRUITING","sponsor":"Centre Paul Strauss","startDate":"2025-06-23","conditions":"Glioblastoma Multiforme, Adult","enrollment":75},{"nctId":"NCT05781321","phase":"PHASE2","title":"Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-03-23","conditions":"Glioblastoma","enrollment":170},{"nctId":"NCT07025226","phase":"EARLY_PHASE1","title":"Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-12","conditions":"Glioma","enrollment":10},{"nctId":"NCT05088798","phase":"PHASE2","title":"Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-09-10","conditions":"Hyperinsulinism","enrollment":100},{"nctId":"NCT04566185","phase":"NA","title":"Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2020-12-16","conditions":"Glioblastoma","enrollment":14},{"nctId":"NCT07274397","phase":"NA","title":"Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Beta Emitting Accurate Monitored Systems","startDate":"2026-01-01","conditions":"Glioblastoma, Brain Tumors, Brain Imaging","enrollment":15},{"nctId":"NCT04306484","phase":"","title":"18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2020-01-01","conditions":"Brain Tumor","enrollment":74},{"nctId":"NCT05762172","phase":"NA","title":"Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2022-02-01","conditions":"Brain Metastases, Radiation Necrosis","enrollment":8},{"nctId":"NCT02856347","phase":"NA","title":"Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2017-03-22","conditions":"Medullary Thyroid Cancer","enrollment":24},{"nctId":"NCT05255159","phase":"PHASE2","title":"Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alberta","startDate":"2022-10-15","conditions":"Neuroendocrine Tumors","enrollment":50},{"nctId":"NCT02104310","phase":"","title":"A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2014-04","conditions":"Malignant Glioma","enrollment":25},{"nctId":"NCT01991977","phase":"PHASE2","title":"18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-12","conditions":"Malignant Glioma","enrollment":91},{"nctId":"NCT00775853","phase":"","title":"Biomarkers of Risk of Parkinson Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2009-05-27","conditions":"Parkinson Disease, Autonomic Nervous System Diseases, Pure Autonomic Failure","enrollment":89},{"nctId":"NCT05103618","phase":"PHASE2","title":"Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA","status":"WITHDRAWN","sponsor":"Andrew Newberg","startDate":"2021-07-08","conditions":"Parkinson Disease, Idiopathic Parkinson Disease","enrollment":""},{"nctId":"NCT01165632","phase":"EARLY_PHASE1","title":"Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-07-26","conditions":"Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma","enrollment":24},{"nctId":"NCT04890028","phase":"NA","title":"Detection and Metabolic Characterization in DOPA PET/CT of Brain Metastases","status":"RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2021-12-03","conditions":"Brain Metastases, MRI","enrollment":52},{"nctId":"NCT04459052","phase":"PHASE2","title":"FDOPA PET and Nutritional Support in Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2020-04-30","conditions":"Parkinson Disease, Idiopathic Parkinson Disease","enrollment":50},{"nctId":"NCT05560009","phase":"","title":"An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-11-10","conditions":"Recurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma","enrollment":9},{"nctId":"NCT03778294","phase":"PHASE2","title":"18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-03-28","conditions":"Glioblastoma, Malignant Glioma","enrollment":43},{"nctId":"NCT07017790","phase":"","title":"Amino Acid PET to Assess the Efficacy of IDH Inhibitor Treatments for IDH Mutated Gliomas","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-06-30","conditions":"Glioma","enrollment":22},{"nctId":"NCT04766632","phase":"NA","title":"Contribution of Cerebral 18F-DOPA PET-CT Scan in High-grade Recurrent Gliomas","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2021-05-18","conditions":"High Grade Glioma","enrollment":16},{"nctId":"NCT01916148","phase":"","title":"18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia","status":"AVAILABLE","sponsor":"Children's Hospital of Philadelphia","startDate":"","conditions":"Congenital Hyperinsulinism (CHI), Beckwith-Wiedemann Syndrome, Insulinoma","enrollment":""},{"nctId":"NCT06880328","phase":"PHASE1","title":"18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-11-07","conditions":"Schizophrenia","enrollment":35},{"nctId":"NCT02020720","phase":"EARLY_PHASE1","title":"18F-DOPA-PET in Planning Surgery in Patients With Gliomas","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-01-22","conditions":"Malignant Glioma, Recurrent Brain Neoplasm","enrollment":72},{"nctId":"NCT04205604","phase":"PHASE2","title":"18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism","status":"RECRUITING","sponsor":"Miguel Pampaloni","startDate":"2016-11-03","conditions":"Congenital Hyperinsulinism","enrollment":50},{"nctId":"NCT04038957","phase":"PHASE1","title":"A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-08-07","conditions":"Schizophrenia","enrollment":22},{"nctId":"NCT05512403","phase":"PHASE3","title":"Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics","status":"RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2023-06-13","conditions":"Glioma","enrollment":88},{"nctId":"NCT02021604","phase":"PHASE1","title":"Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma","status":"RECRUITING","sponsor":"Cook Children's Health Care System","startDate":"2013-10-09","conditions":"Congenital Hyperinsulinism, Insulinoma","enrollment":250},{"nctId":"NCT02646644","phase":"","title":"Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2016-01","conditions":"Neuroendocrine Tumors","enrollment":38},{"nctId":"NCT04870580","phase":"NA","title":"[18F] FDOPA PET Imaging in Glioma: Feasibility Study for PET Guided Brain Biopsy","status":"UNKNOWN","sponsor":"University College, London","startDate":"2021-09-01","conditions":"Glioma","enrollment":21},{"nctId":"NCT03902613","phase":"PHASE4","title":"18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2019-02-07","conditions":"Bipolar Depression","enrollment":1},{"nctId":"NCT05948137","phase":"","title":"F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2017-09-21","conditions":"Pheochromocytoma, Paraganglioma","enrollment":32},{"nctId":"NCT02538315","phase":"","title":"Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients","status":"TERMINATED","sponsor":"University of Saskatchewan","startDate":"2016-10","conditions":"Parkinson's Disease","enrollment":18},{"nctId":"NCT03973502","phase":"NA","title":"Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PD","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-06-12","conditions":"Hepatitis C, Hepatitis B, Parkinson Disease","enrollment":230},{"nctId":"NCT02186678","phase":"NA","title":"Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2014-07-18","conditions":"Paragangliomas, Pheochromocytomas","enrollment":30},{"nctId":"NCT03581305","phase":"PHASE1","title":"PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2018-11-20","conditions":"Depression, HIV Infections, HIV-Associated Cognitive Motor Complex","enrollment":46},{"nctId":"NCT03242824","phase":"PHASE2","title":"The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-09-29","conditions":"Glioma","enrollment":21},{"nctId":"NCT02431715","phase":"","title":"18F-FDOPA PET in Neuroendocrine Tumours","status":"NO_LONGER_AVAILABLE","sponsor":"British Columbia Cancer Agency","startDate":"","conditions":"Thyroid Cancer, Medullary, Carcinoid Tumor, Pheochromocytoma","enrollment":""},{"nctId":"NCT02038348","phase":"PHASE2","title":"Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2016-02-16","conditions":"Metastatic Melanoma","enrollment":5},{"nctId":"NCT00674440","phase":"PHASE2","title":"Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2004-12","conditions":"Congenital Hyperinsulinism, Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy","enrollment":106},{"nctId":"NCT01468454","phase":"PHASE2","title":"Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2009-01","conditions":"Congenital Hyperinsulinism (CHI), Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)","enrollment":130},{"nctId":"NCT04244058","phase":"EARLY_PHASE1","title":"Changes in Glutamatergic Neurotransmission of Severe TBI Patients","status":"SUSPENDED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-09-23","conditions":"Disorder of Consciousness, Traumatic Brain Injury","enrollment":30},{"nctId":"NCT04469244","phase":"","title":"Evaluation of the Use of Radiomics in 18F-FDOPA PET Examinations for the Characterization of Gliomas","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2020-07-01","conditions":"Study on the Use of Radiomics in Gliomas of Initial Disgnosis","enrollment":1000},{"nctId":"NCT00001277","phase":"PHASE2","title":"Studies of Elevated Parathyroid Activity","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1993-12-15","conditions":"Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm","enrollment":1553},{"nctId":"NCT03042416","phase":"PHASE3","title":"18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2017-06-29","conditions":"Congenital Hyperinsulinism, Neuroblastoma, Neuroendocrine Tumors","enrollment":400},{"nctId":"NCT05067192","phase":"","title":"Optimization of Morphomer-based Alpha-synuclein PET Tracers","status":"COMPLETED","sponsor":"Skane University Hospital","startDate":"2021-07-15","conditions":"Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy","enrollment":12},{"nctId":"NCT03998852","phase":"PHASE3","title":"In Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy.","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2021-04-13","conditions":"Apathy","enrollment":30},{"nctId":"NCT00001849","phase":"PHASE2","title":"New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1999-05-20","conditions":"Cushing Syndrome, Endocrine Disease","enrollment":95},{"nctId":"NCT02631655","phase":"NA","title":"POSitron Emission Imaging Using 18F-FDOPA in Neurooncology","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2015-12","conditions":"Glioblastoma","enrollment":110},{"nctId":"NCT04451564","phase":"NA","title":"Understanding and Restoring Dopaminergic Function in Fibromyalgia Patients","status":"UNKNOWN","sponsor":"University of Fribourg","startDate":"2021-03","conditions":"Fibromyalgia","enrollment":80},{"nctId":"NCT04622631","phase":"","title":"Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT","status":"UNKNOWN","sponsor":"Dr. Nayruz Knaana","startDate":"2020-11","conditions":"Neuroendocrine Tumors","enrollment":80},{"nctId":"NCT04618679","phase":"","title":"Application of 18F-FDOPA PET in Research of the Association Between HCV Infection and Parkinson's Disease.","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2020-11-02","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT03903419","phase":"NA","title":"Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients","status":"UNKNOWN","sponsor":"Centre Leon Berard","startDate":"2019-01-16","conditions":"Glioblastomas","enrollment":16},{"nctId":"NCT02533219","phase":"","title":"Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia","status":"NO_LONGER_AVAILABLE","sponsor":"Baylor College of Medicine","startDate":"","conditions":"Hyperinsulinemic Hypoglycemia, Persistent, Congenital Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)","enrollment":""},{"nctId":"NCT01813877","phase":"NA","title":"Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2012-08-22","conditions":"Glioma, Glioblastoma","enrollment":37},{"nctId":"NCT04315584","phase":"EARLY_PHASE1","title":"FDG and FDOPA PET Demonstration of Functional Brain Abnormalities","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2020-03-15","conditions":"Glioblastoma","enrollment":5},{"nctId":"NCT03821961","phase":"NA","title":"18F-FDOPA PET/CT Imaging in Patients Undergoing Metabolic Surgery","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2018-09-03","conditions":"Diabetes Mellitus, Type 2, PreDiabetes, Obesity","enrollment":30},{"nctId":"NCT03525080","phase":"NA","title":"Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors","status":"COMPLETED","sponsor":"Center Eugene Marquis","startDate":"2018-06-12","conditions":"Brain Neoplasms, Adult Brain Tumor","enrollment":16},{"nctId":"NCT02495649","phase":"NA","title":"Evaluation of Myocardial Sympathetic Denervation in Parkinson's Disease Using [18F]FDOPA","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2015-08","conditions":"Parkinson","enrollment":100},{"nctId":"NCT04154254","phase":"NA","title":"Applying PET/MR for Dementia Applications","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2020-01-10","conditions":"Dementia","enrollment":50},{"nctId":"NCT03854942","phase":"PHASE1","title":"Study of the Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2011-08-30","conditions":"Alcohol Addiction","enrollment":43},{"nctId":"NCT03815838","phase":"NA","title":"Molecular Imaging of Pituitary Adenomas","status":"UNKNOWN","sponsor":"Cardiff University","startDate":"2018-04-23","conditions":"Pituitary Adenoma","enrollment":20},{"nctId":"NCT02176720","phase":"PHASE1","title":"Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","startDate":"2014-05","conditions":"Glioma, Glioblastoma, Glioblastoma Multiforme","enrollment":31},{"nctId":"NCT03636945","phase":"NA","title":"Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2018-10","conditions":"Medullary Thyroid Carcinoma","enrollment":62},{"nctId":"NCT03223844","phase":"NA","title":"Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and Release","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2018-01-01","conditions":"Schizophrenia, Psychosis, Sensitisation","enrollment":22},{"nctId":"NCT00094601","phase":"","title":"Relationship of Dopamine to Cognitive Function in Parkinson's Disease","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2004-10-18","conditions":"Parkinson Disease","enrollment":75},{"nctId":"NCT03068520","phase":"NA","title":"Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease Progression?","status":"UNKNOWN","sponsor":"Assuta Medical Center","startDate":"2017-03-01","conditions":"Brain Tumor","enrollment":140},{"nctId":"NCT02175745","phase":"NA","title":"18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas","status":"TERMINATED","sponsor":"Erik Mittra","startDate":"2014-12","conditions":"Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma","enrollment":2},{"nctId":"NCT02371031","phase":"PHASE1","title":"FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2015-03","conditions":"Glioma, Malignant Glioma","enrollment":11},{"nctId":"NCT01248754","phase":"PHASE2","title":"Positron Emission Tomography (PET) With 3,4-dihydroxy-6-18F-fluoro-L-enylalanine (18F-FDOPA) Study","status":"COMPLETED","sponsor":"Alan Nichol","startDate":"2011-07","conditions":"Cancer (High-grace Glioma)","enrollment":20},{"nctId":"NCT02022800","phase":"NA","title":"Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET)","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2013-11","conditions":"Glioma, Cerebral Metastases","enrollment":85},{"nctId":"NCT02801110","phase":"","title":"PET/MR Imaging in Patients With Short and Long Standing Parkinson's Disease","status":"UNKNOWN","sponsor":"david groshar","startDate":"2016-06","conditions":"Idiopathic Parkinson's Disease","enrollment":40},{"nctId":"NCT02539433","phase":"NA","title":"Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2003-12","conditions":"Neuroendocrine Tumors","enrollment":22},{"nctId":"NCT01943097","phase":"","title":"Evaluation of 18F-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2007-06","conditions":"Neuroblastoma","enrollment":160},{"nctId":"NCT00647140","phase":"PHASE2","title":"Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-08","conditions":"Thyroid Neoplasm, Thyroid Carcinoma, Medullary Carcinoma","enrollment":29},{"nctId":"NCT00220272","phase":"PHASE2","title":"Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-01","conditions":"Parkinson Disease","enrollment":183}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":358,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["6-fluoro-L-DOPA","56494","18F-dihydroxyphenylalanine","18F-fluoro-L-dihydroxyphenylalanine","18F-L-Fluoro-DOPA"],"phase":"phase_3","status":"active","brandName":"18F-DOPA","genericName":"18F-DOPA","companyName":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","companyId":"eunice-kennedy-shriver-national-institute-of-child-health-and-human-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"18F-DOPA is a positron emission tomography (PET) imaging agent that accumulates in dopamine-producing tissues, allowing visualization of dopaminergic function and neurological disorders. Used for Imaging of dopaminergic function in Parkinson's disease and parkinsonian syndromes, Evaluation of pediatric movement disorders and neurological conditions affecting dopamine synthesis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":7,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}